Ribociclib and palbociclib-induced erythema multiforme: a case report

Cyclin-dependent kinase 4/6 inhibitors (CKIs), ribociclib, palbocilb and abemaciclib, have been approved in combination with endocrine therapy for the treatment of hormone receptor-positive and human epidermal growth factor 2-negative advanced or metastatic breast cancer. Severe dermatological adver...

Descripción completa

Detalles Bibliográficos
Autores principales: Vrana, Eleni, Mylona, Stella, Bobos, Mattheos, Kontovinis, Loukas, Papazisis, Konstantinos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9693799/
https://www.ncbi.nlm.nih.gov/pubmed/36447465
http://dx.doi.org/10.1093/omcr/omac116

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9693799/
https://www.ncbi.nlm.nih.gov/pubmed/36447465
http://dx.doi.org/10.1093/omcr/omac116

Ejemplares similares